Literature DB >> 9242840

A survey of the attitudes of chronic psychiatric patients living in the community toward their medication.

S Pereira1, R Pinto.   

Abstract

Because non-compliance with antipsychotic drug therapy is both common and associated with a substantially increased risk of acute relapse, depot medication must be preferred for most schizophrenic out-patients. Yet there is a perception that depot medication is unpopular among patients. In the survey of out-patients reported here, the great majority of patients receiving either oral or depot neuroleptics (with or without oral augmentation) would, given a free choice, elect to continue with their present dose form (94% and 87%, respectively). In virtually all cases, the choice of route was made by the treating physician and readily accepted by the patient. These findings suggest that physicians should more often recommend and prescribe depot medication when antipsychotic maintenance therapy is indicated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242840     DOI: 10.1111/j.1600-0447.1997.tb10133.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  15 in total

1.  Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study.

Authors:  Saeko Ikai; Takefumi Suzuki; Masaru Mimura; Hiroyuki Uchida
Journal:  Psychopharmacology (Berl)       Date:  2016-09-08       Impact factor: 4.530

Review 2.  Depot haloperidol decanoate for schizophrenia.

Authors:  S Quraishi; A David
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 3.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Authors:  A Cario Altamura; Francesca Sassella; Annalisa Santini; Clauno Montresor; Sara Fumagalli; Emanuela Mundo
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.

Authors:  Taishiro Kishimoto; Sohag Sanghani; Mark J Russ; Akeem N Marsh; Joshua Morris; Suparna Basu; Majnu John; John M Kane
Journal:  Int Clin Psychopharmacol       Date:  2017-05       Impact factor: 1.659

Review 5.  Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

Authors:  Eduard Parellada; Miquel Bioque
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

6.  Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.

Authors:  Shiyun Kim; Hugo Solari; Peter J Weiden; Jeffrey R Bishop
Journal:  Patient Prefer Adherence       Date:  2012-07-13       Impact factor: 2.711

7.  Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.

Authors:  Borah Kim; Sang-Hyuk Lee; Yen Kuang Yang; Jong-Il Park; Young-Chul Chung
Journal:  Schizophr Res Treatment       Date:  2012-08-14

8.  Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.

Authors:  Rogelio Apiquian; Rodrigo Córdoba; Mario Louzã
Journal:  Neuropsychiatr Dis Treat       Date:  2010-12-22       Impact factor: 2.570

9.  Opinions of French patients with schizophrenia regarding injectable medication.

Authors:  François Caroli; Philippe Raymondet; Isabelle Izard; Joel Plas; Bérengère Gall; Antonio Delgado
Journal:  Patient Prefer Adherence       Date:  2011-03-21       Impact factor: 2.711

10.  Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.

Authors:  David P McDonnell; John Landry; Holland C Detke
Journal:  Int Clin Psychopharmacol       Date:  2014-11       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.